Skip to main content

Media & Press relations

  

Our latest press releases

May 28, 2024

bioMérieux receives FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), an innovative test to improve the assessment of patients with mild traumatic brain injury

bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), a serum-based test to support the assessment of patients with mild traumatic brain injury (mTBI), including concussion.

Swipe for more


Media contacts

Olivier Rescanière

Phone: (+33) (0)4 78 87 20 00 
Email: media@biomerieux.com

_____

Romain Duchez

Phone: (+33) (0)4 78 87 20 00 
Email: media@biomerieux.com


Corporate Library

2023 Annual Report

brochure cover

Corporate Brochure

brochure cover

Antimicrobial Resistance Brochure